NRx Pharmaceuticals

NRx is a clinical-stage pharmaceutical company that is developing ZYESAMI (aviptadil acetate) for COVID-19 and NRX-101, the first oral therapeutic for the treatment of Acute Suicidal Behavior/Ideation (ASIB) in Bipolar Disorder.

Industries

Biotechnology

Headquarters

Wilmington, United States

Stage

Post IPO Equity

Employees

11-50

Links

Org chart

Stephen Willard

CEO & Director

Collapse

Jonathan C. Javitt

Founder & Chief Scientist

Rick Panicucci

Chief Technology Officer

Seth Van Voorhees

Chief Financial Officer

Dennis K. McBride

Chief Strategy Officer & Senior Scientist

Matthew Duffy

Chief Business Officer

Robert Besthof

Head of Operations & Chief Commercial Officer

Philip T. Lavin

Chief Methodologist

Michael Kunz

General Counsel & Corporate Secretary

Martin Brecher

Medical Director

Teams

View all

Leadership Team

8 members

Board of Directors

9 members

CEO and Executive Team

4 members

Founding Team

2 members

Discover similar companies

Cytodyn

Vancouver, United States · Post IPO Equity

Ultivue

Cambridge, United States · Series D

Adaptive Phage Therapeutics

Gaithersburg, United States · Grant

Regeneron

Tarrytown, United States · Post IPO Equity

Be Bio

Cambridge, United States · Series B

Verve Therapeutics

Cambridge, United States · IPO

Biogen

Cambridge, United States

Century Therapeutics

Philadelphia, United States · Post IPO Equity

Guardant Health

Redwood City, United States · Venture

Genentech

South San Francisco, United States · Venture

Natera

Austin, United States · Post IPO Equity

Biomason

Durham, United States · Series C

The Org
helps you hire
great candidates

It takes less than ten minutes to set up your company page.
It’s free to use - try it out today.